Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Abby D. Poms"'
Autor:
C. Gregory Elliott, Eric D. Austin, David Badesch, Jessica Badlam, Raymond L. Benza, Wendy K. Chung, Harrison W. Farber, Kathy Feldkircher, Adaani E. Frost, Abby D. Poms, Katie A. Lutz, Michael W. Pauciulo, Chang Yu, William C. Nichols
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Diagnostic World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) and Diagnostic Group 1' pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) are progressive and fatal disorders. Past regist
Externí odkaz:
https://doaj.org/article/2eaed233510e44b59667460fbb65227a
Autor:
Jessica B, Badlam, David B, Badesch, Eric D, Austin, Raymond L, Benza, Wendy K, Chung, Harrison W, Farber, Kathy, Feldkircher, Adaani E, Frost, Abby D, Poms, Katie A, Lutz, Michael W, Pauciulo, Chang, Yu, William C, Nichols, C Gregory, Elliott, Murali M, Chakinala
Publikováno v:
Chest
BACKGROUND: The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically in the last decade. RESEARCH QUESTION: The United States Pulmonary Hypertension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::157f2a093a8163090339940dd87091fc
https://pubmed.ncbi.nlm.nih.gov/32858008
https://pubmed.ncbi.nlm.nih.gov/32858008
Publikováno v:
Chest. 144(1)
Comorbidities can affect disease progression and/or response to treatment in various conditions. Comorbid conditions are prevalent in patients with pulmonary arterial hypertension (PAH); however, their effect on patient outcomes remains unknown.We ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7151852cc9939f1e5b9fe762c8d923dc
https://pubmed.ncbi.nlm.nih.gov/23348820
https://pubmed.ncbi.nlm.nih.gov/23348820